Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts

Size: px
Start display at page:

Download "Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts"

Transcription

1 Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder mg /day for children and elderly patients mg IM every two weeks Slide 3 Risperidone Prescribing Facts Tablets: 0.25mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg. Orally disintegrating tablets: 0,5 mg, 2 mg Liquid: 1 mg/ml, 30 ml bottle LAI: Risperidone microspheres for IM use. 25 mg, 37.5 mg, 50 mg Stahl, S M. The Prescriber's Guide. 4thd ed. New York: Cambridge University

2 Slide 4 Risperidone Clinical Profile Approved for use in children and adolescents: Schizophrenia, ages 13 and older Acute mania/mixed mania, ages 10 and older Autism related irritability in children, ages 5-16 LAI approved for maintenance treatment of bipolar 1 disorder Stahl, S M. The Prescriber's Guide. 4thd ed. New York: Cambridge University Slide 5 Risperidone Clinical Profile Weight gain: intermediate risk. Lower risk than olanzapine and clozapine Higher risk than aripiprazole and ziprasidone EPS risk is dose dependent. A PET study found that risperidone occupies 75-80% of striatal D2 receptors at a dose of 6mg/day. Prolactin elevation is a risk. Slide 6 Paliperidone Metabolite of risperidone: 9-hydroxylrisperidone Available as LAI: paliperidone palmitate

3 Slide 7 Paliperidone Binding Profile a 1 antagonist a 2 antagonist Slide 8 Paliperidone- Prescribing Facts 6 mg/day (up to 12 mg/day) Extended release tablets: 3 mg, 6 mg, 9 mg LAI - Paliperidone palmitate: 39 mg, 78 mg, 117 mg, 156 mg, 234 mg. INVEGA [package insert]. Accessed at : November 2012 Slide 9 Paliperidone - Clinical Profile First antipsychotic to be approved for schizoaffective disorder. Paliperidone and risperidone are the two SGAs associated with hyperprolactinemia.

4 Slide 10 Quetiapine Binding Profile - 5HT1A partial agonist - H1 antagonist a 1 antagonist Slide 11 Quetiapine Prescribing Facts mg/day for schizophrenia and bipolar mania 300 mg / day for bipolar depression Tablets: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg XR tablets: 200 mg, 300 mg, 400 mg Slide 12 Quetiapine Clinical Profile Approved for: Bipolar maintenance Bipolar depression Acute mania/mixed states Adjunctive treatment of MDD

5 Slide 13 Quetiapine Clinical Profile Adverse effects: Most common adverse effects: somnolence and dizziness. Orthostatic hypotension About 7% of patients Syncope is a possibility with rapid titration Weight gain: intermediate risk EPS: low risk Used in patients with Parkinson s disease and Lewy body dementia Schatzberg, AF., Cole, JO, and DeBattista, C. Manual of Clinical Psychopharmacology. 7th ed.american Psychiatric Publishing, Slide 14 Ziprasidone - Binding Profile - 5HT1A partial agonist - 5HT1D antagonist - 5HT2C antagonist - Low affinity for H1, M1 and a 1 receptors

6 Slide 15 Ziprasidone Prescribing Facts Schizophrenia: mg/day Bipolar disorder: mg/day Maximum daily IM dose: 40 mg Capsules: 20 mg, 40 mg 60 mg, 80 mg Injection: 20 mg/ml Slide 16 Ziprasidone Clinical Profile Associated with QT prolongation: Not dose dependent Careful with: Patients with CV conditions: uncompensated heart failure, cardiac arrhythmias Hypokalemia Hypomagnesemia Bradycardia Use of medications that prolong the QT interval Janicak, P G., Marder S R., and. Pavuluri M N. Principles and Practice of Psychopharmacotherapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins, Slide 17 Ziprasidone Clinical Profile Very low risk of inducing weight gain Patients who are overweight or have metabolic disturbances Dose dependent sedation Janicak, P G., Marder S R., and. Pavuluri M N. Principles and Practice of Psychopharmacotherapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2010.

7 Slide 18 Aripiprazole Binding Profile - Partial D2/D3 agonist (pre and postsynaptic receptors) - 5HT2A antagonist - 5HT1A partial agonist - Modest affinity for H1, M1 and a 1 receptors Slide 19 Aripiprazole Prescribing Facts mg/day Tablets: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg Orally disintegrating tablets: 10 mg, 15 mg Oral solution: 1mg/ml Injection: 9.75 mg/1.3 ml Slide 20 Aripiprazole Clinical Profile Approved as adjunctive treatment for MDD Low risk of causing weight gain Akathisia is a possibility

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second

More information

Antipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics

Antipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics Antipsychotics: The Essentials Module 5: A Primer on Selected Antipsychotics Slide 1 Recently approved antipsychotics Iloperidone (Fanapt) - 2009 Asenapine (Saphris, Sycrest) - 2009 Lurasidone (Latuda)

More information

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer

More information

New Medications in Early Psychosis

New Medications in Early Psychosis New Medications in Early Psychosis Jean Starling Department of Psychological Medicine, the Children s Hospital at Westmead Department of Psychological Medicine and Department of Paediatrics and Child Health,

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Comparison of Atypical Antipsychotics

Comparison of Atypical Antipsychotics PL Detail-Document #281006 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2012 Comparison of

More information

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Abbreviated Class Review: Long-Acting Injectable Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Pharmacotherapy of psychosis and schizophrenia in youth

Pharmacotherapy of psychosis and schizophrenia in youth Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,

More information

Medication Audit Checklist- Antipsychotics - Atypical

Medication Audit Checklist- Antipsychotics - Atypical Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,

More information

Dosing & Administration

Dosing & Administration Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an

More information

Antipsychotics in Bipolar

Antipsychotics in Bipolar Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics

More information

Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics

Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives

More information

BLONANSERIN. THERAPEUTICS Brands Lonasen see index for additional brand names

BLONANSERIN. THERAPEUTICS Brands Lonasen see index for additional brand names BLONANSERIN THERAPEUTICS Brands Lonasen see index for additional brand names Generic? No Class Atypical antipsychotic (serotonin dopamine antagonist; second-generation antipsychotic; also a potential mood

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)

More information

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric

More information

ARIPIPRAZOLE. THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names. Generic? Yes

ARIPIPRAZOLE. THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names. Generic? Yes ARIPIPRAZOLE THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine, serotonin receptor partial agonist

More information

Rexulti (brexpiprazole)

Rexulti (brexpiprazole) Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia

More information

QUETIAPINE. THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names. Generic? Yes

QUETIAPINE. THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names. Generic? Yes QUETIAPINE THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine, serotonin multimodal (DS-MM) Atypical antipsychotic

More information

Lurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action

Lurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify

More information

CYAMEMAZINE. THERAPEUTICS Brands Tercian see index for additional brand names

CYAMEMAZINE. THERAPEUTICS Brands Tercian see index for additional brand names CYAMEMAZINE THERAPEUTICS Brands Tercian see index for additional brand names Generic? Not in the USA Class Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, serotonin dopamine

More information

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors

More information

PALIPERIDONE. THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names

PALIPERIDONE. THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names PALIPERIDONE THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn)

More information

Chapter 161 Antipsychotics

Chapter 161 Antipsychotics Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in

More information

ASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names

ASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names ASENAPINE THERAPEUTICS Brands SAPHRIS see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin, norepinephrine receptor antagonist (DSN-RAn) Atypical

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used

More information

Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical

Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression

More information

LURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names

LURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names LURASIDONE THERAPEUTICS Brands LATUDA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn) Atypical antipsychotic (serotonin-dopamine

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this

More information

THIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes

THIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold

More information

INSTRUCTIONS FOR USE Please read complete instructions prior to use

INSTRUCTIONS FOR USE Please read complete instructions prior to use INSTRUCTIONS FOR USE Please read complete instructions prior to use For deltoid or gluteal intramuscular injection only 3 MONTHS Administer every 3 months 1 With the syringe tip pointing up, shake syringe

More information

What Team Members Other Than Prescribers Need To Know About Antipsychotics

What Team Members Other Than Prescribers Need To Know About Antipsychotics What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State

More information

Drug Use Criteria: Atypical Antipsychotics (oral)

Drug Use Criteria: Atypical Antipsychotics (oral) Texas Vendor Drug Program Drug Use Criteria: Atypical Antipsychotics (oral) Publication History 1. Developed: February 1997 2. Revised: September 2017; September 2015; December 2013; February 2012; June

More information

Treat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering

Treat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective

More information

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency

More information

Indication Initial Dose Recommended Dose Maximum Dose mg/day 750 mg/day. Schizophrenia - Adults (2.2) daily. 25 mg twice

Indication Initial Dose Recommended Dose Maximum Dose mg/day 750 mg/day. Schizophrenia - Adults (2.2) daily. 25 mg twice 3331108 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (quetiapine fumarate) tablets,

More information

ANTIPSYCHOTIC POLYPHARMACY

ANTIPSYCHOTIC POLYPHARMACY Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University

More information

Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents

Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents DRUG NAME INDICATIONS / ACCEPTABLE USES PRIOR STIMULANT/ADHD DRUGS Daytrana (methylphenidate) ADHD

More information

ZIPRASIDONE. THERAPEUTICS Brands Geodon see index for additional brand names

ZIPRASIDONE. THERAPEUTICS Brands Geodon see index for additional brand names ZIPRASIDONE THERAPEUTICS Brands Geodon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS_RAn) Atypical antipsychotic

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

( delirium ) 15%- ( extrapyramidal syndrome ) risperidone olanzapine ( extrapyramidal side effect ) olanzapine ( Delirium Rating Scale, DRS )

( delirium ) 15%- ( extrapyramidal syndrome ) risperidone olanzapine ( extrapyramidal side effect ) olanzapine ( Delirium Rating Scale, DRS ) 2005 6 48-52 Olanzapine 30% ( delirium 5%- Haloperidol ( extrapyramidal syndrome risperidone ( extrapyramidal side effect ( Delirium Rating Scale, DRS ( Delirium ( Olanzapine ( Delirium Rating Scale, DRS

More information

SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009

SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2

More information

Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole

Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2010 Potential control of antipsychotic-induced hyperprolactinemia and

More information

Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications

Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine

More information

Current Non-Preferred Agents

Current Non-Preferred Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Class Update: Oral Antipsychotics

Class Update: Oral Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

What's New in the World of Antipsychotics?

What's New in the World of Antipsychotics? Handout for the Neuroscience Education Institute (NEI) online activity: What's New in the World of Antipsychotics? (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry

More information

in the formulation. (4)

in the formulation. (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use QUETIAPINE TABLETS safely and effectively. See full prescribing information for QUETIAPINE TABLETS.

More information

NEWER ATYPICAL ANTIPSYCHOTICS: NOVEL IDEAS OR

NEWER ATYPICAL ANTIPSYCHOTICS: NOVEL IDEAS OR NEWER ATYPICAL ANTIPSYCHOTICS: NOVEL IDEAS OR METOOS? Sanaz Farhadian, Pharm.D., BCPP Clinical Psychiatric Pharmacist Veterans Affairs Healthcare System, San Diego, CA OBJECTIVES Discuss new antipsychotics

More information

Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents

Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents Pediatr Drugs (2013) 15:217 233 DOI 10.1007/s40272-013-0024-6 REVIEW ARTICLE Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents Silvio Caccia Published online: 16 April

More information

ILOPERIDONE. THERAPEUTICS Brands FANAPT see index for additional brand names. Generic? No

ILOPERIDONE. THERAPEUTICS Brands FANAPT see index for additional brand names. Generic? No ILOPERIDONE THERAPEUTICS Brands FANAPT see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS-RAn) Atypical antipsychotic

More information

Devon A. Sherwood, PharmD, BCPP Assistant Professor of Pharmacy Practice

Devon A. Sherwood, PharmD, BCPP Assistant Professor of Pharmacy Practice Devon A. Sherwood, PharmD, BCPP Assistant Professor of Pharmacy Practice Differentiate dopamine neurotransmitter pathways associated with antipsychotic medications Identify therapy challenges associated

More information

Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy

Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy Adv Ther (2013) 30(2):102 13. DOI 10.1007/s12325-013-0004-9 REVIEW Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy Leslie Citrome To view enhanced content go to www.advancesintherapy.com

More information

February 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by

February 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by February 7-9, 2019 The Westin Fort Lauderdale Florida Provided by Addressing Your Greatest Concerns in Schizophrenia Management: From Suicide to Relapse Prevention and the Role of LAIs John Lauriello,

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

Page 1 of RECENT MAJOR CHANGES Warnings and Precautions, Falls (5.

Page 1 of RECENT MAJOR CHANGES Warnings and Precautions, Falls (5. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use QUETIAPINE FUMARATE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Antipsychotics A. Prescriptions That Require Prior Authorization Prescriptions for Antipsychotics

More information

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved

More information

Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.5, 7.1).

Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.5, 7.1). HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (lurasidone hydrochloride) tablets,

More information

In August 2009, the FDA approved asenapine

In August 2009, the FDA approved asenapine For mass reproduction, content licensing and permissions contact Dowden Health Media. p Asenapine for schizophrenia and bipolar I disorder Jana Lincoln, MD, and Sheldon Preskorn, MD In August 2009, the

More information

Antipsychotic Medications Age and Step Therapy

Antipsychotic Medications Age and Step Therapy Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana

More information

Dosing & Administration

Dosing & Administration Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants.

More information

Psychotic Disorders and the use of Antipsychotic Medications: A Review

Psychotic Disorders and the use of Antipsychotic Medications: A Review Received: 18-10-2012 Accepted: 01-11-2012 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 1 No. 11, Jan 2013 Online Available at: THE PHARMA INNOVATION Psychotic Disorders

More information

Austedo. (deutetrabenazine) New Product Slideshow

Austedo. (deutetrabenazine) New Product Slideshow Austedo (deutetrabenazine) New Product Slideshow Introduction Brand name: Austedo Generic name: Deutetrabenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and

More information

The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in

The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in Antipsychotic Drugs The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in other psychotic and manic states.

More information

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, antiemetic) Commonly Prescribed

More information

Maximum Dose 10 mg. twice daily. 10 mg. twice daily. 10 mg. sublingually. twice daily. 10 mg. twice daily. 10 mg. twice daily

Maximum Dose 10 mg. twice daily. 10 mg. twice daily. 10 mg. sublingually. twice daily. 10 mg. twice daily. 10 mg. twice daily HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use (asenapine) sublingual tablets safely and effectively. See full prescribing information for. (asenapine)

More information

Cariprazine is a newly approved

Cariprazine is a newly approved Cariprazine for schizophrenia and bipolar I disorder Gregory Mattingly, MD, and Richard Anderson, MD, PhD Cariprazine is a newly approved (September 2015) dopamine D3/D2 receptor partial agonist with higher

More information

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction

More information

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components

More information

Quetiapine (SEROQUEL XR), extended-release tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg

Quetiapine (SEROQUEL XR), extended-release tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg Quetiapine Seroquel XR 50 mg, 150mg, 200mg, 300mg and 400mg Extended Release Tablet 0500960/2 Anti-psychotic 1. NAME OF THE MEDICINAL PRODUCT Quetiapine (SEROQUEL XR), extended-release tablets, 50 mg,

More information

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes PERPHENAZINE THERAPEUTICS Brands Trilafon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,

More information

OLANZAPINE tablets USP, for oral use OLANZAPINE orally disintegrating tablets USP, for oral use Initial U.S. Approval: 1996

OLANZAPINE tablets USP, for oral use OLANZAPINE orally disintegrating tablets USP, for oral use Initial U.S. Approval: 1996 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLANZAPINE safely and effectively. See full prescribing information for OLANZAPINE. OLANZAPINE tablets

More information

ONCE-DAILY DOSING WITH NUPLAZID

ONCE-DAILY DOSING WITH NUPLAZID YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication

More information

TRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names

TRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names TRIFLUOPERAZINE THERAPEUTICS Brands Stelazine see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine receptor antagonist (D-RAn) Conventional antipsychotic (neuroleptic,

More information

Drug Class Review. Atypical Antipsychotic Drugs

Drug Class Review. Atypical Antipsychotic Drugs Drug Class Review Atypical Antipsychotic Drugs June 2008 Original Report Date: January 2005 Update 1 Report Date: April 2006 A literature scan of this topic is done periodically The purpose of this report

More information

First Steps: Considering Clozapine for your Patients

First Steps: Considering Clozapine for your Patients First Steps: Considering Clozapine for your Patients The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health

More information

Antipsychotic Use in the Elderly

Antipsychotic Use in the Elderly Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure

More information

Practical Psychopharmacology for More Complex Mental Health Presentations

Practical Psychopharmacology for More Complex Mental Health Presentations MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 2: Antipsychotics & Mood Stabilizers Dr. Ajit Ninan & Joel Lamoure 1 : Who are we?

More information

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective

More information

Objectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition

Objectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change

More information

Regier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016;

Regier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016; Regier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016; Miyamoto 2017 Risperdal Consta (risperidone) Zyprexa Relprevv (olanzapine pamoate) Invega Sustenna (paliperidone palmiate)

More information

Are Two Antipsychotics Better Than One?

Are Two Antipsychotics Better Than One? Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office

More information

Psychiatry in Primary Care: What is the Role of Pharmacist?

Psychiatry in Primary Care: What is the Role of Pharmacist? Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure

More information

Class Update with New Drug Evaluations: Antipsychotics

Class Update with New Drug Evaluations: Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Drug Class Review Atypical Antipsychotic Drugs

Drug Class Review Atypical Antipsychotic Drugs Drug Class Review Atypical Antipsychotic Drugs Final Update 3 Report July 2010 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

APPROACH TO PSYCHOSIS IN PRIMARY CARE

APPROACH TO PSYCHOSIS IN PRIMARY CARE APPROACH TO PSYCHOSIS IN PRIMARY CARE Family Medicine Forum 2015 Annual Meeting Toronto, Ontario November 12-14, 2015 Jon Davine, MD, CCFP, FRCP(C) Associate Professor, McMaster University Objectives

More information

LOXAPINE. THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names. Generic?

LOXAPINE. THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names. Generic? LOXAPINE THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor

More information

Nuplazid. (pimavanserin) New Product Slideshow

Nuplazid. (pimavanserin) New Product Slideshow Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:

More information

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02. Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder

More information

Quetiapine Fumarate Tablets

Quetiapine Fumarate Tablets HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use quetiapine fumarate tablets safely and effectively. See full prescribing information for quetiapine

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.6, 7.1).

Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.6, 7.1). 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (lurasidone hydrochloride) tablets,

More information

Treatment of Schizophrenia

Treatment of Schizophrenia Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,

More information

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) CLeAR Webinar February 14, 2014 Paula Diaz (Pharm) Carol Ward MD Carol Ward Tertiary Mental Health IHA Hillside Centre (Acute Tertiary Mental

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

Page 1 of 40. ZIPRASIDONE hydrochloride capsules, for oral use Initial U.S. Approval: 2001

Page 1 of 40. ZIPRASIDONE hydrochloride capsules, for oral use Initial U.S. Approval: 2001 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZIPRASIDONE HYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for ZIPRASIDONE

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information